# BPC-157 TB-500 References: The Cited Research Record

> BPC-157 TB-500 references: the full citation list behind this digest — preclinical studies, mechanism work, 2024-2026 reviews, and the FDA regulatory sources, with DOIs and PubMed links.

Every quantitative claim on this site maps to an entry below. Peer-reviewed studies and FDA regulatory pages, with DOIs, PubMed IDs, and source URLs.

## How to read this list

The references below are the complete citation record for this digest of BPC-157 TB-500. Entries 1–5 are the foundational constituent studies — the transected-tendon result, the VEGFR2 angiogenesis mechanism, the actin-sequestration structure, the Thymosin Beta-4 mechanism review, and the TB-500 fragment characterization. Entries 6–12 are the 2024–2026 reviews and recent animal studies. Entries 13–15 are the FDA regulatory sources behind the 503A Category 2 status and the scheduled 2026 PCAC review.

Where a study reported animal doses, those appear in the [BPC-157 TB-500 dosage in the literature](/dosage) page as research context only. No human-use protocol is derived from any entry here.

## References

[1] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[2] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[3] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. https://pubmed.ncbi.nlm.nih.gov/15329672/
[4] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/
[5] Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. https://pubmed.ncbi.nlm.nih.gov/22962027/
[6] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
[7] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[8] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[9] Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025. https://pubmed.ncbi.nlm.nih.gov/39861766/
[10] Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury. Medicina (Kaunas). 2025. https://pubmed.ncbi.nlm.nih.gov/40005408/
[11] Multifunctionality and Possible Medical Application of the BPC 157 Peptide - Literature and Patent Review. Pharmaceuticals (Basel). 2025. https://pubmed.ncbi.nlm.nih.gov/40005999/
[12] The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024. https://pubmed.ncbi.nlm.nih.gov/38675421/
[13] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' entries; Category 2, effective with the September 29, 2023 update). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[14] U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 and Category 2 definitions; 503A/503B framework and bulks-list nomination process). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
[15] U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (BPC-157 and TB-500 listed as substances 'being considered for inclusion on the 503A Bulks List'; scheduled discussion, not a decision). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

---

Two repair signals read at a forge's distance — BPC-157's ember leg and TB-500's amethyst leg, each weighed against its own studies, the join between them left theoretical and the FDA 503A status struck first; no clinic at the anvil and nothing here dispensed.